Preclinical Contract Research Services

ImQuest BioSciences is a preclinical contract research and development company that provides service to evaluate the potential of new and novel pharmaceutical products for the treatment and prevention of infectious disease, cancer and inflammatory disease.

As part of our ImQuest SUCCESS platform, we provide expert laboratory research services to define the efficacy and toxicity of pharmaceutical products and specialize in the development of small molecules, natural products, biologics, antimicrobial peptides, therapeutic antibodies and vaccines.

We have expertise in services for antiviral, antimicrobial, and anticancer product development, in vitro toxicology assessment and pharmaceutical product characterization and formulation.

We are committed to earning our client's trust and building long term relationships through collaboration, unwavering commitment to quality science and consistent and effective communication. We understand that each product and each client is unique and we strive to provide effective solutions. Learn More.

What's New

  • Anti-Dengue antibodies enhance Zika virus infection

    As part of our ViroSENS program, ImQuest BioSciences has established an anti-Zika virus cytoprotection assay for multiple strains of Zika virus in multiple cell types.

    Read More


  • HIV Research For Prevention (HIV-R4P)

    October 18-21, 2016
    Chicago, IL
  • American Association of Pharmaceutical Science

    November 13-17, 2016
    Denver, CO

Meet the Team


Anthony Ham, Ph.D

Director, Formulation Science Services

Dr. Ham is the Director of Formulation and Delivery Services at ImQuest. He received his B.S. from the University of Illinois in Chemical Engineering

Read More